Replies to post #230575 on Elite Pharmaceuticals Inc (ELTP)

[Couch]

That post is a keeper! :)

Continue to post is periodically!

It shows what we all know - ELTP massively UNDERVALUED!!

[Perkin78]

Please sticky this post.

[Dr PeteRose MLB]

Excellent post. I saw 10mg methadone hydrochloride listed although most clinics use the liquid for methadone was wondering about Elite being able to acquire the rights to either be a contract manufacter or even better be able to work a deal like with epic and the oxycodone, but try to get some kind of deal. There is a shortage of doctors in the Ohio Kentucky and West Virginia tri state area. All of the doctors in this area are at their maximum number of 100 Suboxone (buprenorphine/naloxone) patients. I do believe congress has uped the maximum number to 250 of patients, but I'm not positive 250 patients is the new maximum number I don't have that info with me. My point is with the rising number of addicts and a shortage of doctors that treat addiction with Suboxone, which is more wildly considered to be the gold standard and people that wanting to get in are put on the waiting list for a spot. Some use Methadone and some of the old timers prefer methadone and people that have to decide whether keep using or go to a methadone clinic while waiting for a call for Suboxone that doesn't come, meanwhile the addict could overdose on heroin if they don't go for methadone.
If Elite could get the rights to liquid methadone or buprenorphine generic tablets just like Nasrat said about the new deal with the high dollar generics a small percentage for Elite could(would) double triple or more yearly revenues.
Good luck to my fellow longs

[Bngo]

Yes I still believe ELTP is way Undervalued!!!

Just listen to the recent CC and see where this company is heading to >>>Nasdaq!


SequestOx will be approved...we are still in the red zone about to reach the end zone!

$$Generic Products$$
Commercial Product
Branded Product Equivalent
Therapeutic Category

1. Hydromorphone Hydrochloride
8 mg Tablets
Dilaudid®
Pain

2. Naltrexone Hydrochloride
50 mg Tablets
Revia®
Opioid Antagonist

3. Phentermine HCl
37.5 mg Tablets
Adipex-P®
Bariatric

4. Phentermine HCI
15 mg and 30 mg Capsules
Adipex-P®
Bariatric

5. Phendimetrazine Tartrate
35 mg Tablets, USP
Bontril®
Bariatric

6. Isradipine
2.5 mg and 5 mg Capsules
N/A
Cardiovascular

7. Hydroxyzine HCI
10 mg, 25 mg, 50 mg Tablets
Atarax®, Vistaril®
Antihistamine

8. Dantrolene Sodium
25 mg, 50 mg and 100 mg Capsules *
Dantrium®
Skeletal Muscle Relaxant

9. Loxapine
5 mg, 10 mg, 25 mg, 50 mg Capsules *
N/A
Antipsychotic

10. Additional Approved ANDA's *
Undisclosed
Undisclosed
* pending manufacturing site transfer



$$Branded Products$$
Commercial Product
Therapeutic Category
Partner

11. Lodrane D®
OTC Allergy
Valeant Pharmaceuticals International, Inc.



$$Contract Manufacturing $$
Commercial Product
Branded Product Equivalent
Therapeutic Category
Partner

12. Methadone Hydrochloride
10 mg Tablets
Dolophine®
Pain
Ascend Laboratories, LLC




$$Generic Pipeline$$

Programs Under Development
Branded Product Equivalent
Therapeutic Category
Development Stage

13. ELI-300 Opioid
Undisclosed
Pain
Early Development

14. ELI-301 Opioid
Undisclosed
Pain
Early Development

15. Oxycodone HCl and Acetaminophen, USP 325 mg
5 mg, 7.5 mg, 10 mg Tablets
Percocet
Pain
Pending FDA Approval

16. Undisclosed Generic
Undisclosed
Undisclosed
Pending FDA Approval



$$Branded Pipeline$$

Development Stage
Partner

17. SequestOxTM (ELI-200) Opioid
Pain
NDA Submitted
PDUFA date: July 14, 2016
Epic Pharma LLC

18. ELI-201 Opioid
Pain
Pivotal Bio-equivalence

19. ELI-202 Opioid
Pain
Pivotal Bio-equivalence

20. ELI-216 Opioid
Pain
Process Development

21. ELI-400 Opioid
Pain
Process Development

22. ELI-500 Opioid
Pain
Process Development

23. ELI-501 Opioid
Pain
Early Development

24. ELI-600 Opioid
Pain
Process Development

25. ELI-601 Opioid
Pain
Early Development

$$26. Elite Announces Development and License Agreement with SunGen Pharma LLC$$
Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into a Development and License Agreement (“Agreement”) with SunGen Pharma, LLC (“SunGen”) to collaborate to develop and commercialize four generic pharmaceutical products.
Under the terms of the agreement, Elite and SunGen will share in the responsibilities and costs in the development of the products. Upon approval, the products will be owned jointly by Elite and SunGen. SunGen shall have the exclusive right to market and sell two of the products using SunGen’s label and Elite shall have the exclusive right to market and sell two of the products using Elite’s label. Elite will manufacture and package all four products on a cost plus basis.
Two of the products are classified as CNS stimulants and two of the products are classified as beta blockers. For the twelve months ending June 30, 2016, the four products and their generic equivalents had total U.S. sales of more than $3 billion according to IMS Health Data.
“We are excited to collaborate with SunGen on the development of these four important generic products,” said Nasrat Hakim, Chairman and CEO of Elite.
“We are thrilled to have this long term strategic partnership with Elite and collaborate in a broad range of product portfolio in development, manufacturing and marketing,” said Dr. Jim Huang, CEO of SunGen.